The Journal of Practical Medicine >
A comparative study of clinical features and lymph node metastasis risk between early multi⁃primary and singlee pulmonary adenocarcinoma nodules
Received date: 2024-08-22
Online published: 2024-11-25
Objective To investigate the clinical characteristics and risk of lymph node metastasis in patients with multiple primary lung adenocarcinoma nodules compared to those with a single lung adenocarcinoma nodule. Methods Retrospective analysis was conducted on 212 patients who underwent thoracic surgery at Zhujiang Hospital of Southern Medical University from 2022 to 2023. This included 149 cases of single lung adenocarcinoma nodules and 63 cases of multiple primary lung adenocarcinoma nodules. After propensity score matching， a comparison was made between the two groups in terms of imaging features， tumor serological indicators， pathological immunohistochemistry， and lymph node metastasis rate. Additionally， binary logistic regression was employed to explore the differences in lymph node metastasis rate between single and multiple nodules. Results After propensity score matching， statistically significant differences were observed in the Avr value of CT （P = 0.001）， KI?67 expression level （P < 0.001）， PD?L1 expression level （P = 0.002）， and lymph node metastasis rate （P = 0.030） between the two groups. However， there were no statistically significant differences in nodule type， imaging features such as lobulation and vascular clustering， tumor serological indicators including CEA and NSE， ALK positive rate， and SYN positive rate. The variables with significant differences （Avr， Ki?67， PD?L1） were identified through Spearman test for correlation analysis. Binary logistic regression analysis was performed using lymph node metastasis as the dependent variable and single or multiple nodules as categorical covariates along with the three correlated variables included as independent variables interactively. The results showed that the probability of lymph node metastasis in multiple primary lung adenocarcinoma nodules was 80.8% lower than that in single lung adenocarcinoma nodules （RR = 0.192， P = 0.042）. Conclusions Multiple primary adenocarcinoma nodules exhibit a less aggressive biological behavior compared to solitary adenocarcinoma nodules， resulting in a reduced likelihood of lymph node metastasis. For cases involving multiple primary lung adenocarcinoma nodules， the implementation of aggressive surgical protocols is not advisable； instead， personalized treatment plans should be developed based on comprehensive evaluations including intraoperative frozen pathology and imaging.
Jiaming YANG , Shi XIE , Haishen ZHOU , Jiaqing ZHANG . A comparative study of clinical features and lymph node metastasis risk between early multi⁃primary and singlee pulmonary adenocarcinoma nodules[J]. The Journal of Practical Medicine, 2024 , 40(22) : 3208 -3214 . DOI: 10.3969/j.issn.1006-5725.2024.22.015
| 1 | BRAY F， LAVERSANNE M， SUNG H， et al. Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin， 2024， 74（3）： 229?263. doi:10.3322/caac.21834 |
| 2 | HAN B， ZHENG R， ZENG H， et al. Cancer incidence and mortality in China， 2022［J］. Natl Cancer Cent， 2024， 4（1）： 47?53. doi:10.1016/j.jncc.2024.01.006 |
| 3 | LEITER A， VELUSWAMY R R， WISNIVESKY J P. The global burden of lung cancer： Current status and future trends［J］. Nat Rev Clin Oncol， 2023， 20（9）： 624?639. doi:10.1038/s41571-023-00798-3 |
| 4 | 吴雪杰，陈东来，朱蓉英，等.多发肺结节的基础研究和临床治疗进展［J］.中国肺癌杂志，2019，22（3）：173-177. |
| 5 | 钟华，姚烽，陈群慧，等.肺部多发结节的诊断和治疗［J］. 中华肿瘤杂志，2023，45（6）：455-463. |
| 6 | ZHANG Y K， CHAI Z， TAN L， et al. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer［J］. World J Surg Oncol， 2017， 15（1）： 1?8. doi:10.1186/s12957-017-1098-3 |
| 7 | NICHOLSON A G， TSAO M S， BEASLEY M B， et al. The 2021 WHO Classification of Lung Tumors： Impact of Advances Since 2015［J］. Thorac Oncol Off Publ Int Assoc Study Lung Cancer，2022， 17（3）： 362?387. doi:10.1016/j.jtho.2021.11.003 |
| 8 | LORTET-TIEULENT J， SOERJOMATARAM I， FERLAY J， et al. International trends in lung cancer incidence by histological subtype： Adenocarcinoma stabilizing in men but still increasing in women［J］. Lung Cancer Amst Neth， 2014， 84（1）： 13?22. doi:10.1016/j.lungcan.2014.01.009 |
| 9 | 中华医学会呼吸病学分会间质性肺疾病学组， 中国医师协会呼吸医师分会间质性肺疾病工作委员会. 中国肺结节病诊断和治疗专家共识［J］. 中华结核和呼吸杂志，2019，42（9）： 685-693. |
| 10 | JIANG L， HE J， SHI X， et al. Prognosis of synchronous and metachronous multiple primary lung cancers： Systematic review and meta-analysis［J］. Lung Cancer Amst Neth， 2015， 87（3）： 303?310. doi:10.1016/j.lungcan.2014.12.013 |
| 11 | 郭海法，毛锋，张辉，等.同时性多原发肺癌的预后及生存相关因素研究［J］.中国肺癌杂志，2017，20（1）：21-27. |
| 12 | 丁小胜，汤传昊，王志杰，等.雌激素在非小细胞肺癌中的研究进展［J］.中国肺癌杂志，2017，20（7）：499-504. |
| 13 | LIU W， KONDURI S D， BANSAL S， et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function［J］. Biol Chem， 2006， 281（15）： 9837?9840. doi:10.1074/jbc.c600001200 |
| 14 | HYDER S M， NAWAZ Z， CHIAPPETTA C， et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor［J］. Cancer Res， 2000， 60（12）： 3183?3190. |
| 15 | IKEDA K， SHIRAISHI K， YOSHIDA A， et al. Synchronous Multiple Lung Adenocarcinomas： Estrogen Concentration in Peripheral Lung［J］. PloS One， 2016， 11（8）： e0160910. doi:10.1371/journal.pone.0160910 |
| 16 | HOFFMAN R M， ATALLAH R P， STRUBLE R D， et al. Lung Cancer Screening with Low-Dose CT： A Meta-Analysis［J］. Gen Intern Med， 2020， 35（10）： 3015?3025. doi:10.1007/s11606-020-05951-7 |
| 17 | YATABE Y， BORCZUK A C， POWELL C A. Do all lung adenocarcinomas follow a stepwise progression？［J］. Lung Cancer Amst Neth， 2011， 74（1）： 7?11. doi:10.1016/j.lungcan.2011.05.021 |
| 18 | ICHINOSE J， KAWAGUCHI Y， NAKAO M， et al. Utility of Maximum CT Value in Predicting the Invasiveness of Pure Ground-Glass Nodules［J］. Clin Lung Cancer， 2020， 21（3）： 281?287. doi:10.1016/j.cllc.2020.01.015 |
| 19 | MARTIN B， PAESMANS M， MASCAUX C， et al. Ki-67 expression and patients survival in lung cancer： Systematic review of the literature with meta-analysis［J］. Br J Cancer， 2004， 91（12）： 2018?2025. doi:10.1038/sj.bjc.6602233 |
| 20 | JI Y， ZHENG M， YE S， et al. PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer［J］. Biomed Res， 2014， 28（6）： 462?467. doi:10.7555/jbr.27.20130084 |
| 21 | RAMI-PORTA R， ASAMURA H， TRAVIS W D， et al. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual［J］. CA Cancer J Clin， 2017， 67（2）： 138?155. doi:10.3322/caac.21390 |
| 22 | 沈涛，卢珠明. 同时性多原发肺癌淋巴结转移规律的临床研究［J］. 岭南现代临床外科， 2021， 21（5）： 561. |
| 23 | LIU W， YANG H S， ZHI F H， et al. Macrophage migration inhibitory factor may contribute to the occurrence of multiple primary lung adenocarcinomas［J］. Clin Transl Med， 2023， 13（10）： e1368. doi:10.1002/ctm2.1368 |
| 24 | SAKURAI T， OKUYAMA Y， KOBAYASHI S， et al. GITR controls intestinal inflammation by suppressing IL-15-dependent NK cell activity［J］. FASEB J Off Publ Fed Am Soc Exp Biol， 2020， 34（11）： 14820?14831. doi:10.1096/fj.202001675r |
| 25 | RONCHETTI S， RICCI E， PETRILLO M G， et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein： A key marker of functional regulatory T cells［J］. Immunol Res， 2015， 2015（1）： 171520. doi:10.1155/2015/171520 |
| 26 | WANG Y， CHEN D， LIU Y， et al. Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers［J］. Cell Death Dis， 2023， 14（7）： 462. doi:10.1038/s41419-023-05992-w |
| 27 | WANG Y， HUANG Z， LI B， et al. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer［J］. CANCER Immunol Immunother， 2024， 73（6）： 111. doi:10.1007/s00262-024-03703-8 |
| 28 | 中华医学会肿瘤学分会， 中华医学会杂志社. 中华医学会肺癌临床诊疗指南（2023版）［J］. 中华医学杂志， 2023， 103（27）： 2037-2074. |
| 29 | WATANABE T， TANAHASHI M， SUZUKI E， et al. Surgical treatment for synchronous multiple primary lung cancer： Is it possible to achieve both curability and preservation of the pulmonary function？［J］. Thorac Cancer， 2021， 12（22）： 2996?3004. doi:10.1111/1759-7714.14164 |
| 30 | ISHIKAWA Y， NAKAYAMA H， ITO H， et al. Surgical treatment for synchronous primary lung adenocarcinomas［J］. Ann Thorac Surg， 2014， 98（6）： 1983?1988. doi:10.1016/j.athoracsur.2014.07.006 |
| 31 | 彭岳， 王晖， 谢厚耐， 等. 同时性多原发肺腺癌的外科治疗及预后［J］. 中国肺癌杂志， 2017， 20（2）： 107?113. |
| 32 | 姜格宁， 陈昶， 朱余明， 等. 上海市肺科医院磨玻璃结节早期肺腺癌的诊疗共识（第一版）［J］. 中国肺癌杂志，2018， 21（3）： 147-159. |
| 33 | 中国医药教育协会肺癌医学教育委员会， 中国胸外科肺癌联盟， 中国抗癌协会肿瘤消融治疗专业委员会，等. 多发磨玻璃结节样肺癌多学科诊疗中国专家共识（2024年版）［J］. 中华内科杂志，2024，63（2）： 153-169. |
| 34 | SUN C， MEZZADRA R， SCHUMACHER T N. Regulation and Function of the PD-L1 Checkpoint［J］. Immunity， 2018， 48（1）： 434?452. doi:10.1016/j.immuni.2018.03.014 |
| 35 | SCHOENFELD A J， RIZVI H， BANDLAMUDI C， et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas［J］. Ann Oncol Off J Eur Soc Med Oncol， 2020， 31（5）： 599?608. doi:10.1016/j.annonc.2020.01.065 |
| 36 | HU C， ZHAO L， LIU W， et al. Genomic profiles and their associations with TMB， PD-L1 expression， and immune cell infiltration landscapes in synchronous multiple primary lung cancers［J］. Immunother Cancer， 2021， 9（12）： e003773. doi:10.1136/jitc-2021-003773 |
| 37 | SODA M， TAKADA S， TAKEUCHI K， et al. A mouse model for EML4-ALK-positive lung cancer［J］. Proc Natl Acad Sci U S A， 2008， 105（50）： 19893?19897. doi:10.1073/pnas.0805381105 |
| 38 | PAN Y， ZHANG Y， LI Y， et al. ALK， ROS1 and RET fusions in 1139 lung adenocarcinomas： A comprehensive study of common and fusion pattern-specific clinicopathologic， histologic and cytologic features［J］. Lung Cancer Amst Neth， 2014， 84（2）： 121?126. doi:10.1016/j.lungcan.2014.02.007 |
| 39 | FAN L， FENG Y， WAN H， et al. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements： A systematic review and meta-analysis［J］. PloS One， 2014， 9（6）； e100866. doi:10.1371/journal.pone.0100866 |
| 40 | CHIA P L， MITCHELL P， DOBROVIC A， et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors［J］. Clin Epidemiol， 2014， 6（1）： 423?432. |
/
| 〈 |
|
〉 |